boomrx #peptides #fda #compoundingpharmacy #clinicalmedicine #patientaccess BoomRX FDA Peptide Category 2 Removal & Public Meeting July 23rd Mansi Hukmani posted on the topic LinkedIn When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved